O	0	1	[
O	1	2	A
O	3	14	multicenter
O	14	15	,
O	16	26	randomized
O	26	27	,
O	28	38	controlled
O	38	39	,
O	40	45	phase
O	46	47	Ⅲ
O	48	56	clinical
O	57	62	study
O	63	65	of
B-intervention	66	69	PEG
I-intervention	69	70	-
I-intervention	70	73	rhG
I-intervention	73	74	-
I-intervention	74	77	CSF
O	78	81	for
O	82	92	preventing
O	93	105	chemotherapy
O	105	106	-
O	106	113	induced
O	114	125	neutropenia
O	126	128	in
B-eligibility	129	137	patients
I-eligibility	138	142	with
I-eligibility	143	149	breast
I-eligibility	150	156	cancer
I-eligibility	157	160	and
I-eligibility	161	164	non
I-eligibility	164	165	-
I-eligibility	165	170	small
I-eligibility	171	175	cell
I-eligibility	176	180	lung
I-eligibility	181	187	cancer
O	187	188	]
O	188	189	.

O	190	192	To
O	193	200	explore
O	201	204	the
O	205	211	safety
O	212	215	and
O	216	224	efficacy
O	225	227	of
O	228	237	pegylated
O	238	249	recombinant
O	250	255	human
O	256	267	granulocyte
O	268	274	colony
O	274	275	-
O	275	286	stimulating
O	287	293	factor
O	294	295	(
O	295	298	PEG
O	298	299	-
O	299	302	rhG
O	302	303	-
O	303	306	CSF
O	306	307	)
O	308	310	in
O	311	321	preventing
O	322	334	chemotherapy
O	334	335	-
O	335	342	induced
O	343	354	neutropenia
O	355	357	in
O	358	366	patients
O	367	371	with
O	372	378	breast
O	379	385	cancer
O	386	389	and
O	390	393	non
O	393	394	-
O	394	399	small
O	400	404	cell
O	405	409	lung
O	410	416	cancer
O	417	418	(
O	418	423	NSCLC
O	423	424	)
O	424	425	,
O	426	429	and
O	430	432	to
O	433	440	provide
O	441	444	the
O	445	450	basis
O	451	454	for
O	455	463	clinical
O	464	475	application
O	475	476	.

O	477	486	According
O	487	489	to
O	490	493	the
O	494	503	principle
O	504	506	of
O	507	511	open
O	511	512	-
O	512	517	label
O	517	518	,
O	519	529	randomized
O	529	530	,
O	531	539	parallel
O	539	540	-
O	540	545	group
O	546	556	controlled
O	557	565	clinical
O	566	571	trial
O	571	572	,
O	573	576	all
O	577	585	patients
O	586	590	were
O	591	601	randomized
O	602	604	by
O	605	606	1
O	606	607	∶
O	607	608	1
O	608	609	∶
O	609	610	1
O	611	615	into
O	616	621	three
O	622	628	groups
O	629	631	to
O	632	639	receive
O	640	643	PEG
O	643	644	-
O	644	647	rhG
O	647	648	-
O	648	651	CSF
O	652	655	100
O	656	657	μ
O	657	658	g
O	658	659	/
O	659	661	kg
O	661	662	,
O	663	666	PEG
O	666	667	-
O	667	670	rhG
O	670	671	-
O	671	674	CSF
O	675	676	6
O	677	679	mg
O	679	680	,
O	681	683	or
B-control	684	687	rhG
I-control	687	688	-
I-control	688	691	CSF
O	692	693	5
O	694	695	μ
O	695	696	g
O	696	697	/
O	697	699	kg
O	699	700	,
O	701	713	respectively
O	713	714	.

O	715	718	The
O	719	727	patients
O	728	732	with
O	733	739	breast
O	740	746	cancer
O	747	755	received
O	756	759	two
O	760	772	chemotherapy
O	773	779	cycles
O	779	780	,
O	781	784	and
O	785	788	the
O	789	794	NSCLC
O	795	803	patients
O	804	812	received
O	813	814	1
O	814	815	-
O	815	816	2
O	817	823	cycles
O	824	826	of
O	827	839	chemotherapy
O	840	849	according
O	850	852	to
O	853	858	their
O	859	868	condition
O	868	869	.

O	870	873	All
O	874	882	patients
O	883	887	were
O	888	895	treated
O	896	900	with
O	901	904	the
O	905	916	combination
O	917	929	chemotherapy
O	930	932	of
O	933	936	TAC
O	937	938	(
O	938	947	docetaxel
O	947	948	+
O	949	959	epirubicin
O	959	960	+
O	961	977	cyclophosphamide
O	977	978	)
O	979	981	or
O	982	984	TA
O	985	986	(
O	986	995	docetaxel
O	995	996	+
O	997	1007	epirubicin
O	1007	1008	)
O	1008	1009	,
O	1010	1012	or
O	1013	1016	the
O	1017	1029	chemotherapy
O	1030	1032	of
O	1033	1042	docetaxel
O	1043	1051	combined
O	1052	1056	with
O	1057	1068	carboplatin
O	1068	1069	,
O	1070	1074	with
O	1075	1076	a
O	1077	1079	21
O	1080	1083	day
O	1084	1089	cycle
O	1089	1090	.

O	1091	1094	The
O	1095	1103	duration
O	1104	1106	of
O	1107	1112	grade
O	1113	1114	3
O	1114	1115	-
O	1115	1116	4
O	1117	1128	neutropenia
O	1129	1131	in
O	1132	1135	the
O	1136	1139	PEG
O	1139	1140	-
O	1140	1143	rhG
O	1143	1144	-
O	1144	1147	CSF
O	1148	1151	100
O	1152	1153	μ
O	1153	1154	g
O	1154	1155	/
O	1155	1157	kg
O	1158	1161	and
O	1162	1165	PEG
O	1165	1166	-
O	1166	1169	rhG
O	1169	1170	-
O	1170	1173	CSF
O	1174	1175	6
O	1176	1178	mg
O	1179	1185	groups
O	1186	1190	were
O	1191	1198	similar
O	1199	1203	with
O	1204	1208	that
O	1209	1211	in
O	1212	1215	the
O	1216	1219	rhG
O	1219	1220	-
O	1220	1223	CSF
O	1224	1225	5
O	1226	1227	μ
O	1227	1228	g
O	1228	1229	/
O	1229	1231	kg
O	1232	1237	group
O	1238	1239	(
O	1239	1240	P
O	1240	1241	>
O	1241	1242	0
O	1242	1243	.
O	1243	1245	05
O	1246	1249	for
O	1250	1253	all
O	1253	1254	)
O	1254	1255	.

O	1256	1259	The
B-outcome	1260	1269	incidence
I-outcome	1270	1274	rate
I-outcome	1275	1277	of
I-outcome	1278	1283	grade
I-outcome	1284	1285	3
I-outcome	1285	1286	-
I-outcome	1286	1287	4
I-outcome	1288	1299	neutropenia
O	1300	1302	in
O	1303	1306	the
O	1307	1310	PEG
O	1310	1311	-
O	1311	1314	rhG
O	1314	1315	-
O	1315	1318	CSF
O	1319	1322	100
O	1323	1324	μ
O	1324	1325	g
O	1325	1326	/
O	1326	1328	kg
O	1329	1334	group
O	1334	1335	,
O	1336	1339	PEG
O	1339	1340	-
O	1340	1343	rhG
O	1343	1344	-
O	1344	1347	CSF
O	1348	1349	6
O	1350	1352	mg
O	1353	1358	group
O	1358	1359	,
O	1360	1363	and
O	1364	1365	G
O	1365	1366	-
O	1366	1369	CSF
O	1370	1371	5
O	1372	1373	μ
O	1373	1374	g
O	1374	1375	/
O	1375	1377	kg
O	1378	1383	group
O	1384	1388	were
B-iv-bin-percent	1389	1391	69
I-iv-bin-percent	1391	1392	.
I-iv-bin-percent	1392	1393	7
I-iv-bin-percent	1393	1394	%
O	1394	1395	,
B-iv-bin-percent	1396	1398	68
I-iv-bin-percent	1398	1399	.
I-iv-bin-percent	1399	1400	4
I-iv-bin-percent	1400	1401	%
O	1401	1402	,
O	1403	1406	and
B-cv-bin-percent	1407	1409	69
I-cv-bin-percent	1409	1410	.
I-cv-bin-percent	1410	1411	5
I-cv-bin-percent	1411	1412	%
O	1412	1413	,
O	1414	1426	respectively
O	1426	1427	,
O	1428	1432	with
O	1433	1434	a
O	1435	1438	non
O	1438	1439	-
O	1439	1450	significant
O	1451	1461	difference
O	1462	1467	among
O	1468	1471	the
O	1472	1477	three
O	1478	1484	groups
O	1485	1486	(
O	1486	1487	P
O	1487	1488	=
O	1488	1489	0
O	1489	1490	.
O	1490	1493	963
O	1493	1494	)
O	1494	1495	.

O	1496	1499	The
B-outcome	1500	1509	incidence
I-outcome	1510	1514	rate
I-outcome	1515	1517	of
I-outcome	1518	1525	febrile
I-outcome	1526	1537	neutropenia
O	1538	1540	in
O	1541	1544	the
O	1545	1548	PEG
O	1548	1549	-
O	1549	1552	rhG
O	1552	1553	-
O	1553	1556	CSF
O	1557	1560	100
O	1561	1562	μ
O	1562	1563	g
O	1563	1564	/
O	1564	1566	kg
O	1567	1572	group
O	1572	1573	,
O	1574	1577	PEG
O	1577	1578	-
O	1578	1581	rhG
O	1581	1582	-
O	1582	1585	CSF
O	1586	1587	6
O	1588	1590	mg
O	1591	1596	group
O	1597	1600	and
O	1601	1602	G
O	1602	1603	-
O	1603	1606	CSF
O	1607	1608	5
O	1609	1610	μ
O	1610	1611	g
O	1611	1612	/
O	1612	1614	kg
O	1615	1620	group
O	1621	1625	were
B-iv-bin-percent	1626	1627	6
I-iv-bin-percent	1627	1628	.
I-iv-bin-percent	1628	1629	1
I-iv-bin-percent	1629	1630	%
O	1630	1631	,
B-iv-bin-percent	1632	1633	6
I-iv-bin-percent	1633	1634	.
I-iv-bin-percent	1634	1635	4
I-iv-bin-percent	1635	1636	%
O	1636	1637	,
O	1638	1641	and
B-cv-bin-percent	1642	1643	5
I-cv-bin-percent	1643	1644	.
I-cv-bin-percent	1644	1645	5
I-cv-bin-percent	1645	1646	%
O	1646	1647	,
O	1648	1660	respectively
O	1660	1661	,
O	1662	1669	showing
O	1670	1672	no
O	1673	1684	significant
O	1685	1695	difference
O	1696	1701	among
O	1702	1706	them
O	1707	1708	(
O	1708	1709	P
O	1709	1710	=
O	1710	1711	0
O	1711	1712	.
O	1712	1715	935
O	1715	1716	)
O	1716	1717	.

O	1718	1721	The
B-outcome	1722	1731	incidence
I-outcome	1732	1736	rate
I-outcome	1737	1739	of
I-outcome	1740	1747	adverse
I-outcome	1748	1754	events
O	1755	1757	in
O	1758	1761	the
O	1762	1765	PEG
O	1765	1766	-
O	1766	1769	rhG
O	1769	1770	-
O	1770	1773	CSF
O	1774	1777	100
O	1778	1779	μ
O	1779	1780	g
O	1780	1781	/
O	1781	1783	kg
O	1784	1789	group
O	1789	1790	,
O	1791	1794	PEG
O	1794	1795	-
O	1795	1798	rhG
O	1798	1799	-
O	1799	1802	CSF
O	1803	1804	6
O	1805	1807	mg
O	1808	1813	group
O	1814	1817	and
O	1818	1819	G
O	1819	1820	-
O	1820	1823	CSF
O	1824	1825	5
O	1826	1827	μ
O	1827	1828	g
O	1829	1830	/
O	1831	1833	kg
O	1834	1839	group
O	1840	1844	were
B-iv-bin-percent	1845	1846	6
I-iv-bin-percent	1846	1847	.
I-iv-bin-percent	1847	1848	7
I-iv-bin-percent	1848	1849	%
O	1849	1850	,
B-iv-bin-percent	1851	1852	4
I-iv-bin-percent	1852	1853	.
I-iv-bin-percent	1853	1854	1
I-iv-bin-percent	1854	1855	%
O	1855	1856	,
O	1857	1860	and
B-cv-bin-percent	1861	1862	5
I-cv-bin-percent	1862	1863	.
I-cv-bin-percent	1863	1864	5
I-cv-bin-percent	1864	1865	%
O	1865	1866	,
O	1867	1879	respectively
O	1879	1880	,
O	1881	1888	showing
O	1889	1890	a
O	1891	1894	non
O	1894	1895	-
O	1895	1906	significant
O	1907	1917	difference
O	1918	1923	among
O	1924	1928	them
O	1929	1930	(
O	1930	1931	P
O	1931	1932	=
O	1932	1933	0
O	1933	1934	.
O	1934	1937	581
O	1937	1938	)
O	1938	1939	.

O	1940	1942	In
O	1943	1951	patients
O	1952	1956	with
O	1957	1963	breast
O	1964	1970	cancer
O	1971	1974	and
O	1975	1978	non
O	1978	1979	-
O	1979	1984	small
O	1985	1989	cell
O	1990	1994	lung
O	1995	2001	cancer
O	2002	2003	(
O	2003	2008	NSCLC
O	2008	2009	)
O	2010	2020	undergoing
O	2021	2024	TAC
O	2024	2025	/
O	2025	2027	TA
O	2028	2040	chemotherapy
O	2040	2041	,
O	2042	2043	a
O	2044	2050	single
O	2051	2054	100
O	2055	2056	μ
O	2056	2057	g
O	2057	2058	/
O	2058	2060	kg
O	2061	2070	injection
O	2071	2073	or
O	2074	2075	a
O	2076	2082	single
O	2083	2088	fixed
O	2089	2090	6
O	2091	2093	mg
O	2094	2098	dose
O	2099	2101	of
O	2102	2105	PEG
O	2105	2106	-
O	2106	2109	rhG
O	2109	2110	-
O	2110	2113	CSF
O	2114	2116	at
O	2117	2119	48
O	2120	2125	hours
O	2126	2131	after
O	2132	2144	chemotherapy
O	2145	2149	show
O	2150	2158	definite
O	2159	2170	therapeutic
O	2171	2177	effect
O	2178	2182	with
O	2183	2184	a
O	2185	2188	low
O	2189	2198	incidence
O	2199	2201	of
B-outcome	2202	2209	adverse
I-outcome	2210	2216	events
I-outcome	2217	2220	and
I-outcome	2221	2225	mild
I-outcome	2226	2233	adverse
I-outcome	2234	2243	reactions
O	2243	2244	.

O	2245	2253	Compared
O	2254	2258	with
O	2259	2262	the
O	2263	2273	continuous
O	2274	2279	daily
O	2280	2289	injection
O	2290	2292	of
O	2293	2296	rhG
O	2296	2297	-
O	2297	2300	CSF
O	2301	2302	5
O	2303	2304	μ
O	2304	2305	g
O	2305	2306	/
O	2306	2308	kg
O	2308	2309	/
O	2309	2310	d
O	2310	2311	,
O	2312	2313	a
O	2314	2320	single
O	2321	2324	100
O	2325	2326	μ
O	2326	2327	g
O	2327	2328	/
O	2328	2330	kg
O	2331	2340	injection
O	2341	2343	or
O	2344	2345	a
O	2346	2352	single
O	2353	2358	fixed
O	2359	2360	6
O	2361	2363	mg
O	2364	2368	dose
O	2369	2371	of
O	2372	2375	PEG
O	2375	2376	-
O	2376	2379	rhG
O	2379	2380	-
O	2380	2383	CSF
O	2384	2387	has
O	2388	2395	similar
O	2396	2402	effect
O	2403	2406	and
O	2407	2409	is
O	2410	2414	more
O	2415	2427	advantageous
O	2428	2430	in
O	2431	2441	preventing
O	2442	2454	chemotherapy
O	2454	2455	-
O	2455	2462	induced
O	2463	2474	neutropenia
O	2474	2475	.
